Anupam Mukherjee

Employment

• ICMR-National Institute of Virology Scientist E, RAMANUJAN Fellow & Associate Professor
  2025 - Present
• ICMR-National Institute of Translational Virology and AIDS Research Scientist E & Head of the Division
  2023 - Present
• ICMR-National Institute of Translational Virology and AIDS Research Scientist D & Head of the Division
  2021 - 2023
• ICMR-National Institute of Translational Virology and AIDS Research Scientist D
  2019 - 2021
• National Institute of Cholera and Enteric Diseases RAMANUJAN Fellow Scientist
  2016 - 2021
• ICMR-National Institute of Cholera and Enteric Diseases DST-Young Scientist
  2015 - 2016
• University of Calcutta DS Kothari Fellow
  2015 - 2015
• Saint Louis University Postdoctoral Research Associate
  2013 - 2015
• ICMR-National Institute of Cholera and Enteric Diseases Postdoctoral Research Fellow
  2011 - 2013

Education

• National Institute of Cholera and Enteric Diseases Ph.D
  2007 - 2011
• University of Calcutta M.Sc
  2004 - 2006
• University of Calcutta B.Sc
  2001 - 2004

Projects & Funding

Projects & funding information is unavailable.

Publications (94)

• Mesoporous silica nanoparticle-mediated delivery of a synergistic 5-miRNA combination inhibits HSV-2 infection.
  Scientific reports 2026 DOI: 10.1038/s41598-026-55793-2
  +Save
• Development and analytical validation of a dual-gene isothermal assay for Nipah virus detection.
  Applied microbiology and biotechnology 2026 DOI: 10.1007/s00253-026-13932-9
  +Save
• TWEEZER
  Design Patent: 474574-001-28-03, Journal No: 03/2026 2026
  +Save
• Immunoinformatics for HSV-2 Vaccine Design
  Systems Immunology and Translational Research in Infectious diseases 2026 DOI: 10.3389/978-2-8325-7493-5
  +Save
• Network-based integration of hsa-miR-150-5p reveals key regulatory roles in HIV-HCV coinfection and HCV-associated hepatocellular carcinoma
  Virology 2026 DOI: 10.1016/j.virol.2025.110747
  +Save
• Co-delivery of dolutegravir and carbon-nanoparticles using niosomal platform for enhanced anti-HIV and pharmacokinetic activity
  European Journal of Pharmaceutics and Biopharmaceutics 2026 DOI: 10.1016/j.ejpb.2025.114963
  +Save
• Organoids Gone Viral: A Comprehensive Review on Human Organoid Models to Study Viral Pathogenesis
  Viruses 2026 DOI: 10.3390/v18020238
  +Save
• Discovery of Piplartine as a Potent Multitargeting Anti‐HIV and Anti‐TB Lead Molecule: Network Pharmacology, in silico, and in vitro Studies to Analyze Its Role in HIV/TB Coinfection
  ChemistrySelect 2026
  +Save
• Decoding Host Cell–Virus Interactions: Translational Advances in Antiviral Immunity and Therapeutics (4th Edition)
  Viruses 2026 DOI: 10.3390/v18030286
  +Save
• Harnessing dual therapeutic properties of phytoconstituents with anti-HIV and anti-cancer activities
  Next Research 2026 DOI: 10.1016/j.nexres.2025.101269
  +Save